IPO registrations (S-1, F-1) · Registrants
Lucira Health, Inc.
- SEC CIK
- 1652724 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2021-01-15, last 2021-02-01; 1 initial registration, 1 amendment
- Outcome
- Final prospectus filed 2021-02-08; declared effective 2021-02-04
- Industry (SIC)
- In Vitro & In Vivo Diagnostic Substances 2835
- Incorporated in
- DE
- Business address
- 1315 63RD STREET, Emeryville, CA 94608
- EIN
- 27-2491037
- EDGAR entity type
- operating
- Insiders and CEO pay
- Lucira Health, Inc. on the corporate pages
Offering terms
- Proposed price range
- $15.00–$17.00 per share (S-1/A filed 2021-02-01)
- Final price
- $17.00 per share, within the range (424B4 filed 2021-02-08, an initial public offering)
- Shares sold
- 9,000,000
- Gross proceeds
- $153,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol LHDX
- Lead underwriters
- BofA Securities; William Blair
- Syndicate
- LifeSci Capital
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: Lucira Health, Inc. Fuzzy (name and state)
- Form 5500 plan sponsor: LUCIRA HEALTH, INC EXACT (EIN (EXACT))
- Federal award recipient: LUCIRA HEALTH INC Fuzzy (name and state)
- Form D issuer: Lucira Health, Inc. EXACT (CIK (EXACT))
- Lobbying client: LUCIRA HEALTH Fuzzy (name and state)
- SEC filer: Lucira Health, Inc. EXACT (CIK (EXACT))
Filings 5
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-01-15 | S-1 | S-1 (registration) | Lucira Health, Inc. | 0001193125-21-010174 ↗ |
| 2021-02-01 | S-1/A | S-1/A (amendment) | Lucira Health, Inc. | 0001193125-21-023778 ↗ |
| 2021-02-04 | S-1MEF | S-1MEF (added securities) | Lucira Health, Inc. | 0001193125-21-029315 ↗ |
| 2021-02-04 | EFFECT | EFFECT (declared effective) | Lucira Health, Inc. | 9999999995-21-000444 ↗ |
| 2021-02-08 | 424B4 | 424B4 (final prospectus) | Lucira Health, Inc. | 0001193125-21-031881 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-02-01 | S-1/A | registration statement | $15.00–$17.00 | 7,812,500 | - | Nasdaq LHDX | 3 | primary document; range, shares headline, cover names 3 | document ↗ | |
| 2021-02-08 | 424B4 | final prospectus | $17.00 | 9,000,000 | $153,000,000 | Nasdaq LHDX | 3 | primary document; price sentence, shares headline, proceeds table, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Boeding Chad | Other | 3 | 2021–2022 | ||
| Eclipse Fund III, L.P. | TenPercentOwner | 2 | 2021 | ||
| Eclipse GP III, LLC | TenPercentOwner | 2 | 2021 | ||
| Eclipse Ventures Fund I, L.P. | TenPercentOwner | 2 | 2021 | ||
| Eclipse Ventures GP I, LLC | TenPercentOwner | 2 | 2021 | ||
| Engelson Erik T. | Director,Officer | President and Chief Executive | 8 | 2021–2023 | |
| EPIQ Capital Group, LLC | Other; TenPercentOwner | 3 | 2021–2022 | ||
| EPQ LLC, LCOVD PS | TenPercentOwner | 3 | 2021–2022 | ||
| EPQ LLC, LCOVD SAFE PS | Other | 3 | 2021–2022 | ||
| EPQ LLC, LFLU PS | Other; TenPercentOwner | 3 | 2021–2022 | ||
| GARDINER SANDRA A. | Director | 2 | 2021–2022 | ||
| George Dan | Officer | CFO and Treasurer | 6 | 2021–2022 | |
| HARTMANN HANSGREGORY C. | Officer | Chief Operating Officer | 4 | 2021 | |
| Lamond David | Director | 3 | 2021–2022 | ||
| Lewis Brezoczky Kelly | Officer | Executive Vice President | 4 | 2021 | |
| Mitra Debkishore | Director,Officer | Chief Technology Officer | 5 | 2021–2022 | |
| Prashar Tamanna | Officer | Vice President | 5 | 2021–2022 | |
| Rogers Erica J. | Director | 2 | 2021–2022 | ||
| Susan Lior | Director,TenPercentOwner | 3 | 2021–2022 | ||
| Tablak Steve | Director | 2 | 2021–2022 | ||
| Yen Tuff | Director | 3 | 2021–2022 | ||
| EPQ LLC, LTEST PS | Other | 2 | 2021–2022 | ||
| Collins Kevin Walter | Officer | Chief Revenue Officer | 5 | 2021–2023 | |
| Kashmolah Ghazi | Officer | Ex VP & Chief Quality Officer; Ex. VP &Chief Quality Officer | 9 | 2021–2023 | |
| Allen Anthony Joseph | Officer | Chief Operations Officer | 6 | 2021–2023 | |
| McCauley Alison | Director | 3 | 2021–2022 | ||
| Narido Richard Clavano | Officer | Chief Financial Officer; Interim CFO | 3 | 2022–2023 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2019-08-07 | Lucira Health, Inc. | Biotechnology | $32,500,000 | $32,500,000 | 30 | 2 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | Lucira Health, Inc. | CA | State business registries | name and state |
| Federal award recipient | LUCIRA HEALTH INC | CA | Federal spending (USAspending) | name and state |
| Form D issuer | Lucira Health, Inc. | CA | Form D private offerings | CIK (EXACT) |
| Lobbying client | LUCIRA HEALTH | CA | Federal lobbying (LDA) | name and state |
| Paying company | Lucira Health, Inc. | CA | Open Payments (drug and device company payments) | name and state |
| Patent assignee | Lucira Health, Inc. | CA | Patents (USPTO) | name and state |
| SEC filer | Lucira Health, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | LUCIRA HEALTH, INC. | CA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | LUCIRA HEALTH, INC | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry In Vitro & In Vivo Diagnostic Substances, CA first:
- ANSYS DIAGNOSTICS INC CA
- Monogram Biosciences, Inc. CA
- ARGONAUT TECHNOLOGIES INC CA
- GENENCOR INTERNATIONAL INC CA
- Intuity Medical, Inc. CA
- Global Wholehealth Partners Corp CA
- Alpha Teknova, Inc. CA
- ALERE SAN DIEGO, INC. CA
- AVIGEN INC \DE CA
- Anbio Biotechnology 2M
In other datasets, the same topic (Health) in CA:
- Nonprofit: 24 HOUR CANCER DANCE-A-THON (Nonprofits (IRS Form 990))
Interests: In Vitro & In Vivo Diagnostic Substances · Health